# Data Sheet (Cat.No.T1637)



## Deferoxamine Mesylate

### **Chemical Properties**

CAS No.: 138-14-7

Formula: C26H52N6O11S

Molecular Weight: 656.79

Appearance: no data available

store at low temperature, keep away from direct

Storage: sunlight

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

### **Biological Description**

Description	Deferoxamine Mesylate (DFOM) is an iron chelator and iron death inhibitor.  Deferoxamine Mesylate binds free iron into a stable complex and reduces iron accumulation. Deferoxamine Mesylate up-regulates HIF-1α levels and induces apoptosis.
Targets(IC50)	Mitophagy,Beta Amyloid,Others,Ferroptosis,HIF/HIF Prolyl-Hydroxylase,Autophagy
In vitro	METHODS: Human cervical cancer cells HeLa were treated with Deferoxamine Mesylate (3-100 μM) for 72 h, and cell numbers were detected using the Incucyte HD imaging system.  RESULTS: Deferoxamine Mesylate inhibited cell growth in a concentration-dependent manner, and significant growth inhibition was observed at 100 μΜ. [1]  METHODS: Human colorectal cancer cells HT29 and HCT116 were treated with Deferoxamine Mesylate (50-200 μM) for 48 h, and the expression levels of target proteins were detected by Western Blot.  RESULTS: Deferoxamine Mesylate induced significant expression of HIF-1α in a dosedependent manner. [2]  METHODS: Human breast cancer cells MDA-MB-231 and MCF-7 were treated with Deferoxamine Mesylate (200 μM) for 24 h. Apoptosis was detected by Flow Cytometry.  RESULTS: After Deferoxamine Mesylate treatment, the apoptosis rate of MDA-MB-231 cells was unchanged compared with untreated cells, while apoptosis of MCF-7 cells was significantly increased. [3]
In vivo	METHODS: To investigate whether Deferoxamine Mesylate reduces inflammation and atherosclerosis in experimental mice, Deferoxamine Mesylate (100 mg/kg) was administered intraperitoneally to apolipoprotein E-deficient (apoE-/-) mice once a day for 10 weeks.  RESULTS: Deferoxamine Mesylate reduced the development of aortic atherosclerotic lesions by 26% Deferoxamine Mesylate also reduced serum MCP-1 levels and gene expression of proinflammatory and macrophage markers in the aorta and heart, and increased protein expression of transferrin receptors in the heart and liver. In contrast, Deferoxamine Mesylate treatment had no effect on serum cholesterol and triglyceride levels. [4]  METHODS: To study the effect of Deferoxamine Mesylate on adipocyte dysfunction in adipose tissue of ob/ob mice epididymis, Deferoxamine Mesylate (100 mg/kg) was

Page 1 of 3 www.targetmol.com

	injected intraperitoneally into ob/ob mice once daily for fifteen days. <b>RESULTS</b> : Deferoxamine Mesylate significantly improved important parameters of adipose tissue biology by decreasing the secretion of reactive oxygen species and inflammatory markers, by increasing the levels of antioxidant enzymes, HIF-1 $\alpha$ , and HIF-1 $\alpha$ -targeted proteins, and by altering adipocyte iron-, glucose-, and lipid-related metabolic proteins. Meanwhile, hypertrophic adipocytes were reduced in size and insulin signaling pathway-related proteins were activated after Deferoxamine Mesylate treatment. [5]
Cell Research	After cells were seeded onto the collagen-GAG discs and allowed to adhere for 3?hours, they were placed into a hypoxic incubator with 1% O2 or incubated under standard cell culture conditions with deferoxamine mesylate (DFO) added to final concentrations of 30, 60, or 120?µM. Scaffolds seeded with AdMSCs cultured under standard conditions were used as a control [3].
Animal Research	The animals were divided into 4 groups: sham, SAH, SAH+vehicle and SAH+DFX (100mg/kg) group. DFX was administered intraperitoneally 2 and 6 hours after hemorrhage followed by every 12 hours for a maximum of 7 days. The same time course and dosage of saline were administered in the SAH+vehicle group. Afterward, rats underwent behavioral testing and were euthanized at day 1, 3, 7 and 28 for brain water content calculation, immunohistochemistry or western blot assays. The study was performed in three parts. Part 1 measured the brain water content, Evan's blue extravasation, and ultrastructural abnormalities at day 1, 3 and 7 after SAH to evaluate the time-dependent changes in brain edema and BBB disruption (n = 4 per time point and group). Part 2 investigated the role of iron in SAH-induced BBB disruption at day 1, 3 and 7 by brain water content (n = 4, per time point and group), Evan's blue extravasation (n = 4, per time point and group), transmission electron microscopy (n = 4, per time point and group) and western blot analysis (n = 3, per time point and group). Part 3 compared the acute (n = 61, per group at day 1; n = 42, per group at day 3; n = 23, per group at day 7) and long term (n = 4, per group at day 28) neurological function after SAH in each group to determine the effect of iron chelation on SAH-induced neurologic impairment [4].

## **Solubility Information**

Solubility	DMSO: 152.3 mM,	
	H2O: 20.83 mg/mL (31.72 mM)	
	(< 1 mg/ml refers to the product slightly soluble or insoluble)	

#### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.5226 mL	7.6128 mL	15.2256 mL
5 mM	0.3045 mL	1.5226 mL	3.0451 mL
10 mM	0.1523 mL	0.7613 mL	1.5226 mL
50 mM	0.0305 mL	0.1523 mL	0.3045 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Page 2 of 3 www.targetmol.com

#### Reference

Fujisawa K, et al. An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells. Cancer Metab. 2022 May 12;10(1):8.<br/>br/>Bi G,



This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 Address:36 Washington Street, Wellesley Hills, MA 02481 E\_mail:info@targetmol.com

Page 3 of 3 www.targetmol.com